see minim risk expect /podd/tndm best
posit post revenu upsid three compani outperform
broader med-tech ytd valuat well averag notabl except
arguabl render near-term risk/reward bit less compel still like
long-term outlook link remain top pick
model revenu consensu ultim think could post
beat seem larg line buy-sid expect per earli
discuss jen outperform libr like launch
next month work hand open item fda
seemingli clear posit catalyst share next month although new
algorithm expect year-end close monitor expect stock
move materi higher result
howev continu view core long-term hold best product
pipelin sensor softwar vast under-penetrated market opportun
believ investor focu competit price dynam particular
overdon continu execut vs expect launch late
like drive stock higher stock cheap
ev/sal p/fcf despit repres discount vs dxcm
histor multipl vs howev continu believ share worth
per dcf analysi see downsid limit also convict
intermitt cgm continu glucos monitor eventu becom standard
care non-intens type patient could drive signific long term upsid vs
expect remain top pick diabet devic
expect rel benign quarter see minim risk revenu
expect see path modest upsid although gross margin could come
bit light consensu impli manag guidanc look
current expect meaning upsid vs consensu expect envis
path occur importantli see clear neg catalyst stock
horizon launch repres excit upcom
catalyst keep sentiment posit
deni valuat tough trade sale
premium vs base case dcf also suggest fair valu
downgrad acknowledg right may best time initi full
posit howev still stock wed want especi long-
term invest horizon clear path revenu growth next
year nearli recur revenu attract gross margin
profit ramp differenti competit posit tubeless
option autom insert pharmaci channel strong manag team
upsid case dcf suggest share could approach horizon launch
excit medium-term catalyst share rais price target blend
base case/upsid case dcf continu like long-term outlook
see minim downsid risk beyond would buyer weak throughout
pleas see page report import disclosur
dont expect repres materi upsid downsid catalyst investor
appear like continu focus outlook probabl
primari driver recent share weak said see minim risk consensu
expect reason path beat
see three factor make setup rel less attract past
year view lack room signific revenu upsid anima
tailwind expir multipl competit launch horizon howev
low believ share mostli price less compel
setup continu strong confid competit posit via
believ share like deserv valu discount vs less recur
revenu long term margin potenti current discount
ev/ basi appear bit overdon maintain price target base dcf
repres ev/ discount vs arguabl best
product pipelin pump industri control-iq sport/phon control next gen algorithm
expect continu take notabl market share next
year manag also made impress gain gross margin past year
improv long term profit outlook dont current see ton room
upsid beyond price target next month low
continu view risk/reward attract
increas price target maintain target
pleas see page overview revenue/ep
thomson eikon cowen compani
thomson eikon cowen compani
thomson eikon cowen compani
thomson eikon cowen compani
thomson eikon cowen compani
forecast revenu consensu though ultim think
could exceed consensu revenu expect ep
expect
rel model notabl sourc upsid vs alreadi
consensu revenu forecast via new patient addit revenu estim
assum total new patient addit declin q/q vs inconsist
histor season trend new patient add typic slightli increas
assum overal new patient add flat q/q instead
q/q revenu estim would higher
consensu see reason new patient momentum would slow
dxcm core market still under-penetrated competitor abt result
demonstr continu market strength consist solid libr prescript data
see limit risk consensu estim expect anoth solid beat
current model revenu ep consensu
expect respect view forecast reason anyth believ
bia could upsid
averag annual revenu per patient declin y/i impli price
headwind averag sensor transmitt util per patient flat
slightli vs y/i see limit downsid risk assumpt
biggest driver potenti upsid like new patient addit
new patient forecast assum sharp deceler us cgm market growth
annual cgm volum growth go
sustain howev also believ limit risk above-consensu
revenu forecast clear potenti upsid particularli tout
significantli increas advertis music ear increas
awareness/fingerstick convers via libr clear tailwind
outsid estim revis expect move upward worth note
updat true real world perform abt libr confirm
launch timelin late key catalyst monitor stock
continu view core long term hold best product pipelin
sensor softwar vast under-penetrated market opportun
believ investor focu competit price dynam particular
overdon continu execut vs expect launch
late like drive stock higher ev/sal
p/fcf may cheap despit repres discount vs dxcm
year histor multipl vs howev continu believ share
worth per dcf analysi see downsid limit also
convict cgm eventu becom standard care non-intens type
patient could drive signific long term upsid vs expect
remain top pick diabet devic
outperform p-t
overal expect rel benign quarter modestli reduc
revenu forecast though remain line consensu still
see path upsid howev dont expect repeat signific
beat also worth note could modest gross margin
downsid quarter consensu estim dont appear fulli contempl
manag commentari regard headwind new us facil ramp
rel model see greatest potenti revenu upsid within
us ou omnipod estim model us/ou revenu near high end
guidanc though continu see potenti path upsid region
driven new patient add higher util vs guidanc
increas revenu forecast though remain
consensu expect biggest delta forecast vs consensu like drug
deliveri expect declin expect global diabet growth
off-set result total compani revenu growth
continu like setup share enter clear neg catalyst
tndm sport launch closest neg catalyst envis
horizon launch like acceler new patient addit
gain market share today despit vendor without cgm-autom
featur horizon launch add autom insulin deliveri well enabl phone
control effect elimin devic patient repres huge catalyst
dont current expect meaning upsid vs consensu revenu expect
envis path occur compani result survey data
suggest us insulin pump market acceler us new patient
start come mdi amongst best posit benefit
acceler expect begin expand new ou geographi
beyond start smaller eu countri current presenc
could clear driver upsid vs current forecast
ou revenu growth could achiev via exist ou market alon
neg point stock valuat trade
sale premium vs base case dcf also suggest fair valu
downgrad acknowledg right may
best time initi full posit howev still stock wed want
especi long term invest horizon clear path
revenu growth forese futur nearli recur revenu
attract gross margin current manag target
recent site visit chuck apulch give us confid room
expans beyond differenti competit posit tubeless option
autom insert pharmaci channel strong manag team
upsid case dcf suggest share could approach horizon launch
excit medium term catalyst share rais price target
continu like long term outlook see minim downsid
risk beyond wed buyer weak throughout
dont expect repres materi upsid downsid catalyst investor
appear like continu focus outlook seemingli driver recent
share weak due potenti neg catalyst note exceed
consensu revenu expect averag past quarter
intern bolu anima convers seen like moder
move forward dont expect anoth signific blow-out result said
minim risk consensu expect reason path
reduc revenu forecast though continu model revenu
consensu expect forecast assum overal new patient
shipment declin q/q driven entir q/q intern declin
accordingli forecast assum us new patient shipment increas q/q
higher q/q increas histor season trend import
note still benefit anima convers us
us new patient add awar upcom control-iq
launch/th abil remot upgrad seemingli high reason lead us
believ stronger typic season trend
coupl factor make setup share rel
less compel recent histori appear less room revenu upsid
investor grown accustom recent quarter anima convers
signific driver new patient shipment total new patient
shipment us new shipment declin materi vast
major patient alreadi chosen new pump multipl new competit
system expect launch contrari
compani launch meaning new product primari
howev still believ consensu expect reasonable/achiev
consensu revenu expect appear impli overal new patient add
flat vs expect ou shipment declin off-set us
new shipment grow assum continu captur
overal us mdi convers similar share mdi patient switch
pump would need add patient via competit convers
exclud anima base current
estim reach revenu forecast
first blush increment non-anima competit convers could appear
aggress context new launch
horizon howev specif primari sourc competit
convers worth note two specif tailwind
patient renew pool patient target
per ada present possibl remain anima
opportun greater expect recal patient still warranti
time anima exit elig receiv free pump
warranti period expir could mean decent chunk anima patient
purchas pump still grab unless use patient
popul basi expect greater renew sale
dont think case given bolu shipment lock patient
waitlist late
ultim primari driver confid us new patient add growth
control-iq launch expect fda approv immin certainli year end
give least quarter head start even
launch expect control-iq compet effect critic
differenti clinic data control-iq impress perhap importantli
feedback weve receiv clinic trial investig eas use/train
system stellar
figur new patient shipment breakdown data cowen estim
compani report cowen compani
believ low share mostli price rel less
compel still attract setup share deserv discount vs
less recur revenu long term margin potenti view current
discount ev/ basi appear bit overdon maintain
price target base dcf repres ev/ discount vs
arguabl best product pipelin pump industri control-iq sport/phon
control next gen algorithm expect continu take notabl
market share next year manag also made impress gain
gross margin past year improv long term profit outlook
dont current see ton room upsid beyond price target next
month low continu view risk/reward attract
new patient current cowen forecast new declin due anima product still drive solid ou resultsu new us competit total global new pt share mdi conversionsmdt said patient renew cowen
compani report thomson eikon cowen compani
quarterli snapshot dexcomconfer call novemb et dial-in passcod vs consensu mm except re-affirmed re-affirmed oper non-gaap revenu metric mm except statement mm except per count reduc ep forecast though remain consensu revenu upsid drive increment ep upsid vs forecast increas revenu forecast forecast revenu consensu expect still believ bia upsid forecast increment upsid possibl greatest sourc upsid vs model new patient add forecast assum new patient add declin q/q flat q/q would add forecast consensu appear conserv reduc gross margin forecast manag note expect similar q/q increas gross margin increas forecast q/q increas slightli reduc forecast verili payment accordingli forecast assum underli q/q increas expens increas sg forecast sg flat q/q past two year forecast assum larg flat q/q though y/i reduc oper margin forecast driven reduct gross margin forecast increas sg forecast forecast remain consensu revenu upsid drive oper profit increas durabl revenu forecast continu see clear path upsid current forecast assum new patient add declin q/q vs flat would add overal revenu forecast see reason new patient demand remain least stabl vs penetr core market remain low indic soften demand anyth indic continu robust demand includ ship earli like due manufactur capac continu solid libr prescript data trend larg maintain sensor revenu forecast modest fx adjust forecast assum price util stabl vs level see ton room underli upsid outsid better expect new patient addit would add sensor revenu well cowen
compani report thomson eikon cowen compani
quarterli snapshot insuletconfer call novemb pm et dial-in passcod vs consensu mm except flat y/i due scale new facil re-affirmed oper msd oper margin revenu metric mm except statement mm except market earn per count maintain forecast maintain forecast maintain forecast reduc oper margin forecast driven entir modest reduct revenu forecast forecast line consensu reduc us omnipod forecast forecast remain near high end guidanc primari driver reduct forecast modest reduct new patient add forecast estim previous high revenu forecast assum new patient add trend similar y/i basi similar histor trend q/q basi msd see limit risk vs forecast could see modest upsid maintain ou revenu forecast forecast high end guidanc continu believ bia upsid guidanc appear impli notabl q/q declin util per patient attribut season europ summer may ultim play manag guid see littl risk guidance/our forecast potenti solid upsid manag conserv regard season expect beat vs high end guidanc maintain ep forecast consensu expect expect meaning upsid downsid strong revenu perform could drive upsid although possibl gross margin come expect maintain drug deliveri revenu forecast line midpoint manag guidanc limit visibl sale outsid manag guidanc base mostli forecast provid largest custom make total drug deliveri sale onpro reach market share august although neulasta sale us continu declin due biosimilar pressur expect meaning upsid downsid vs guidanc reduc revenu forecast entir within us forecast reduc new patient add estim forecast remain slightli consensu albeit larg line view bia upsid forecast potenti driven us ou diabet busi said envis anoth blow-out quarter exceed revenu return modest beats/rais maintain gross margin forecast consensu expect manag guid investor expect step gross margin trough way forecast assum total step accordingli consensu could aggress possibl manag easili exce guidanc achiev consensu prefer remain conserv cowen
compani report thomson eikon cowen compani
quarterli snapshot tandemconfer call novemb pm et dial-in passcod vs consensu mm except adj ebitda margin break even revenu metric mm except growth statement mm except earn per y/i nmnmnmshare count reduc revenu forecast see ton upsid potenti forecast absent better expect ou perform forecast shipment repres q/q declin due entir ou busi blow-out bolu anima convers expect ou shipment declin q/q within us forecast larg consist histor trend assum us new patient shipment increas q/q also worth note overal pump shipment aid renew shipment maintain suppli revenu forecast repres q/q growth surfac q/q growth rate would appear conserv howev similar pump revenu bolu ou demand moder us forecast consist histor trend abl least reach forecast reduc revenu forecast entir within pump forecast revenu forecast consensu bottom basi see ton room upsid beyond forecast said potenti upsid via better ou result assum materi q/q declin limit visibl besid manag commentari and/or bolu anima patient end suppli distribut near quarter end regardless also see limit downsid risk especi vs consensu estim reduc oper profit forecast due reduct revenu forecast maintain sg forecast maintain forecast reduc gross margin forecast due lower pump revenu mix forecast remain consensu cowen
compani report cowen compani
companyproductcommerci timelinesdistinguish enhanc late possibl improv outlier perform day perform reduc warm time late earli broad roll-out tbd decis support systemsmedtronicnon-adjunct guardian stand-alone us april fda submiss impli fda submiss like late earli reduct fingerstick vs guardian expect meet icgm criteria synergyu fda submiss impli late earli submiss like mid late launch fulli dispos volum reduct new step insert still expect requir day calibr abbottlibr fda submiss earli approv immin address open item fda ou launch octob termtbasenseonicseversens dayu clinic trial expect run like launch ou launch dayus/ tbdextend wear day us/ou tbdagamatrix waveform cascadeu expect launchou expect late launchlifescan/nova biomedicaltbdu tbdou earli cgmu tbdou launch tbdou select market launch submit fda seemingli launch ou launch august icgm systemus/ tbdimplant sensor extern receiv year sensor life like requir calibr bit bulki non-invas cgm patch skin electr current draw glucos skin report strong accuraci metric although data appear like replic real world skeptic given challeng non-invas monitor intern work aid typezero acquisit action treatment recommend mdi user core featur current libr factori calibr day wear trend data plu alerts/alarm still requir interrog sensor glucos data like materi perform improv base icgm commentari data present ada made clear much pipelin includ addit analyt beyond glucos solid accuracy/reli per clinic trial data physician check product still requir calibr non-adjunct claim like inferior accuraci requir calibr seemingli shorter wear time limit detail date technolog acquir isens earli seemingli current market leader despit inclus calibr data shown accuraci peer eas use inferior leader requir calibr long term market viabil unclear pend improv continu glucos monitor cgm product pipelin tracker dispos miniatur lower cost mayb day wear like perform improv reduc calibr one day unclear mani thereaft insulin dose claim like enabl reimburs geograph specif commentari like launch along insulin pen partner lilli novo etc start late earli term flash capabl batteri incorpor sensor remov transmitt addit analyt cowen
compani report cowen compani
productcommerci timelinesdistinguish target april launchou tbd person close loop us fda submiss impli late earli submiss like mid late launch ou tbdhorizonu launchou tbdloopu observ studi on-going time suggest late launch possibl ou expect launch tandemcontrol-iqu launch ou launcht sportu tbdtidepoolloopu observ studi conclud bionicsilet insulin onlyu earli launch pivot expect initi tbdilet dual hormoneu launch like year post insulin launch ou tbdbigfoot biomedicalloopu like inject bigfoot smart pen/dss like launch pivot trial time disclos timelin frequent delay pump hardwar asant abbott cgm bigfoot autom insulin deliveri algorithm limit clinic data date also plan consolid prescript except insulin eli lillyhybrid close loop commerci name yet disclos us/ou like launch insulin pen launch launch screen durabl pump pre-fil insulin cartridg close loop develop timelin tbd us expect ou alreadi launch us tbdothersroch eoflow sfc fluidic inreda cambridgetbddisk shape pump design deka cgm clinic data share date hybrid close loop run android control current use kaleido pump though explor option cgm insulin pump product pipelin tir target includ correct bolus waterproof expect time close loop close loop smartphon control earli time rang data amongst broad subset patient includ young pede encourag somewhat near commerci dual-hormon system develop util glucagon zealand theoret reduc sever hypoglycemia risk iphon app like approv part fda interoper initi new algorithm class similar icgm/ac pump current offici partner app resid patient smartphon miniatur pump screen phone control bolu button devic integr cgm control-iq algorithm insulin version util either cgm clinic data date solid tir focus simplic throughout user oper requir patient weight start small medium larg meal input predict algorithm modul suspend basal insulin deliveri cgm also autom correct bolus clinic data tir minim time hypo perhap importantli patient feedback data tir smartphon control meal predict although limit detail safeti protocol loop algorithm do-it-yourself commun taken fda tidepool compat icgm ace pump sign partner cowen
compani report thomson eikon cowen compani
mm except per share day profit re-affirmed re-affirmed day gener oper non-gaap adjust non-gaap day day less long termnet earn per consensu estim mm except per share gross op cowen
compani report thomson eikon cowen compani
mm except profit flat y/i due scale new facil re-affirmed target previous oper y/i msd oper margin target mid-teensincrement non-oper expens interest major interest expens non-cashearn per except per share gross op consensu estim cowen
compani report thomson eikon cowen compani
mm except cagrcommentstot profit oper adj ebitda margin break even posit non-cash stock aincrement interest earn per cowen vs consensu cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
